Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety

Toxicologic Pathology

Volumn 34, Issue 1, 2006, Pages 81-90

  Gintant, Gary ^a   Su, Zhi ^a   Martin, Ruth ^a   Cox, Bryan ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

APD; Arrhythmias; HERG; QT interval; Repolarization; Torsades de Pointes

Indexed keywords

ANILIDE; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CISAPRIDE; DOFETILIDE; FLUOXETINE; FLUVOXAMINE; KETOCONAZOLE; MESORIDAZINE; MESYLIC ACID DERIVATIVE; N (3,4 DIMETHOXYPHENYL) N [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; NEUROLEPTIC AGENT; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERFENADINE; UNCLASSIFIED DRUG; VERAPAMIL;

ACTION POTENTIAL; ANGINA PECTORIS; BINDING ASSAY; BIOASSAY; CARDIOTOXICITY; CHROMOSOME 7Q; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; ECG ABNORMALITY; ELECTRIC ACTIVITY; ELECTROCARDIOGRAM; GASTROINTESTINAL REFLUX; HEART ARRHYTHMIA; HEART DISEASE; HEART ELECTROPHYSIOLOGY; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HUMAN; HYPERTENSION; HYPOKALEMIA; ION CURRENT; LONG QT SYNDROME; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; SEX DIFFERENCE; TORSADE DES POINTES; VOLTAGE CLAMP;

ANIMALS; ANIMALS, LABORATORY; BIOLOGICAL MARKERS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HEART CONDUCTION SYSTEM; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; TORSADES DE POINTES;

EID: 33644647859     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1080/01926230500431376     Document Type: Review

References (90)

1. Ahmad, S. R., and Wolfe, S. M. (1995). Cisapride and Torsades de pointes. Lancet 345, 508
2. Bril, A., Gout, B., Bonhomme, M., Landais, L., Faivre, J. F., Linee, P., Poyser, R. H., and Ruffolo, R. R. Jr. (1996). Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL32872. J Pharm Exp Ther 276(2), 637-46.
3. Brown, A. M. (2004). Drugs, hERG and sudden death. Cell Calcium 35(6), 543-7.
4. Brunswick, D. J., Amsterdam, J. D., Fawcett, J., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., and Beasley, C. M. Jr. (2002). Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment. J Affect Disord 68(2-3), 243-9. (Fluox)
5. + current in cardiac myocytes by dofetilide. J Pharmacol Experim Ther 262(2), 809-17. (Dofet)
6. Chiang, C. E. (2004). Congenital and acquired long QT syndrome. Current concepts and management. Cardiol Rev 12(4), 222-34.
7. ++ current in Guinea pig ventricular myocytes by cisapride. J Biomed Sci 11(3), 303-14. (Cisa)
8. + channels. J Pharmacol Sci 95, 311-9.
9. Chouabe, C., Drici, M. D., Romey, G., Barhanin, J., and Lazdunski, M. (1998). HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54(4), 695-703. (Verap)
10. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995). A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 80(5), 795-803.
11. Kr) channel. J Cardiovasc Electrophysiol 15(11), 1302-9. (Cisa, Dofet, Verap)
12. Davies, A. J., Harindra, V., McEwan, A., and Ghose, R. R. (1989). Cardiotoxic effect with convulsions in terfenadine over dose. Br Med J 298, 325. (Terf)
13. Desai, M., Li, L., Desta, Z., Malik, M., and Flockhart, D. (2003). Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 55(6), 511-7.
14. Dessertenne, F. (1966). La tachycardia ventriculaire a deux foyers opposes variables. Arch Mal Coeur 59, 263-72.
15. o. J Pharmacol Toxicol Meth 50(3), 187-99.
16. Dresser, G. K., Spence, J. D., and Bailey, D. G. (2000). Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38(1), 41-57.
17. Drolet, B., Khalifa, M., Daleau, P., Hamelin, B. A., and Turgeon, J. (1998). Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval. Circulation 97(2), 204-10. (Cisa)
18. DRUGDEX® System: Klasco, R. K. (Ed): DRUGDEX® System. Thomson Micromedex. Greenwood Village Colorado (Edition expires 2006). Accessed August 15, 2005.
19. Dubin, A. E., Nasser, N., Rohrbacher, J., Hermans, A. N., Marrannes, R., Grantham, C., Van Rossem, K., Cik, M., Chaplan, S. R., Gallacher, D., Xu, J., Guia, A., Byrne, N. G., and Mathes, C. (2005). Identifying modulators of hERG channel activity using the PatchXpress PlanarPatch Clamp. J Biomolec Screen 10(2), 168-81.
20. Fermini, B., and Fossa, A. A. (2003). The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Rev Drug Disco V 2, 439-47.
21. Fenichel, R. R., Malik, M., Antzelevitch, C., Sanguinetti, M., Roden, D. M., Priori, S. G., Ruskin, J. N., Lipicky, R. J., and Cantilena, L. R. (2004). Drug induced Torsades-de-Pointes and implications for drug development. J Cardiovasc Electrophys 15(4), 475-95.
22. Ficker, E., Kuryshev, Y. A., Dennis, A. T., Obejero-Paz, C., Wang, L., Hawryluk, P., Wible, B. A., and Brown, A. M. (2004). Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66(1), 33-44.
23. Fossa, A. A., Wisialowski, T., Wolfgang, E., Wang, E., Avery, M., Raunig, D. L., and Fermini, B. (2004). Differential effect of hERG blocking agents on cardiac electrical alternans in the guinea pig. Eur J Pharmacol 486, 209-21. (Cisa, Verap)
24. Fossa, A. A., Wisialowski, T., Mangano, A., Wolfgang, E., Winslow, R., Gorczyca, W., Crimin, K., and Raunig, D. L. (2005). Dynamic beat-to-beat modeling of th QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go related gene inhibition. J Pharmacol Exp Ther 312(1), 1-11.
25. Fozzard, H. A. (1992). Afterdepolarizations and triggered activity. Basic Res Cardiol 87 (Suppl 2), 105-13.
26. Gintant, G. A. (2000). Characterization and functional consequences of delayed rectifier current transient in ventricular repolarization. Am J Physiol (Heart Circ Physiol) 278, H806-17.
27. Gintant, G. A., Limberis, J. T., McDermott, J. S., Wegner, C. D., and Cox, B. F. (2001). The Canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharm. 37, 607-18.
28. Gladziwa, U., Bares, R., Klotz, U., Dakshinamurty, K. V., Ittel, T. H., Seiler, K.-U., and Sieberth, H.-G. (1991). Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis. Clin Pharmacol Ther 50, 673-81 (Cisa).
29. Guo, L., and Guthrie, H. (2005). Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Tox Methods 52(1), 123-35.
30. Haverkamp, W., Breithardt, G., Camm, A. J., Janse, M. J., Rosen, M. R., Antzelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A., and Shah, R. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Res 47, 219-33.
31. Honig, P. K., Worthan, D. C., Zamani, K., Conner, D. P., Mullin, J. C., and Cantilena, L. R. (1993). Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269(12), 1550-2.
32. January, C. T., Chau, V., and Makielski, J. C. (1991). Triggered activity in the heart: cellular mechanisms of early after-depolarizations. Eur Heart J 12(suppl F), 4-9.
33. + currents in guinea-pig ventricular myocytes. Br J Pharmacol 131, 1809-16 (Verap).
34. + current by dofetilide. Circ Res 72, 75-83 (Dofet).
35. + channel HERG. Mol Pharmacol. 59(1), 122-6.
36. Kass, R. S., and Moss, A. J. (2003). Long QT syndrome: novel insights into the mechanisms of cardiac arrhythmias. J Clin Invest 112(6), 810-5.
37. Kirsch, G. E., Trepakova, E. S., Brimecombe, J. C., Sidach, S. S., Erickson, H. D., Kochan, M. C., Shyjka, L. M., Lacerda, A. E., and Brown, A. M. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Meth 50(2), 93-101 (Cisa, Fluox, Terf, Verap).
38. Kongsamut, S., Kang, J., Chen, X-L., Roehr, J., and Rampe, D. (2002). A comparison of the receptor binding of HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450(1), 37-41.
39. Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., Reynolds, W., and Rampe, D. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther 312(1), 316-23.
40. Lacy C. F., Armstrong, L., Goldman, M. P., and Gance, L. L. (1999). Drug Information Handbook, 7th ed, 1999-2000. Am Pharm Ass'n. (Fluox). Hudson, Ohio, USA.
41. 2+ channel current in rat ventricular myocytes by terfenadine. Circ Res. 81(2), 202-10 (Terf).
42. + Channels. J Physiol. 537 (Pt 3), 843-51.
43. Malik, M. (2002). The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 25(2), 209-16.
44. Malik, M., and Camm, A. J. (2001). Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling. Drug Saf 24(5), 323-51.
45. Martin, R. L., McDermott, J. S., Salmen, H. J., Palmatier, J., Cox, B. F., and Gintant, G. A. (2004). The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of Multi-Channel Block. J Cardiovasc Pharm 43(3), 369-79. (Cisa., Fluox., Terf.)
46. Milnes, J. T., Crociani, O., Arcangeli, A., Hancox, J. C., and Witchel, H. J. (2003a). Blockade of hERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139(5), 887-98.
47. Milnes, J. T., Dempsey, C. E., Ridley, J. M., Crociani, O., Arcangeli, A., Hancox, J. C., and Witchel, H. J. (2003b). Perferential closed channel blockade of HERG potassium currents by chemically synthesized BeKm-1 scorpion toxin. FEBS Lett 547, 20-6.
48. + channels in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 26(5), 761-9 (Terf).
49. Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., and Sanguinetti, M. C. (2000). A structural basis for drug-induced long QT syndrome. PNAS 97(22), 12329-33.
50. Monahan, B. P., Ferguson, C. L., Killeavy, E. S., Lloyd, B. K., Troy, J., and Cantilena, L. R. (1990). Torsades de pointes occurring in association with terfenadine use. J Amer Med Assoc, 264, 2788-90 (Terf).
51. ++ channels in ventricular myocytes from rat heart. J Pharmacol Exp Ther 285(2), 546-52 (Verap).
52. Netzer, R., Bischoff, U., and Ebneth, A. (2003). HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Devel 6(4), 462-9.
53. Pacher, P., Magyar, J., Szigligeti, P., Banyasz, T., Pankucsi, C., Korom, Z., Ungvari, Z., Kecskemeti, V., and Nanasi, P. P. (2000). Electrophysiological effects of fluoxetine in mammalian cardiac tissues. Naunyn Schmiedebergs Arch Pharmacol 361(1), 67-73 (Fluox).
54. Park, K. S., Kong, I. D., Park, K. C., and Lee, J. W. (1999). Fluoxetine inhibits L-type Ca2+ and transient outward K+ currents in rat ventricular myocytes. Yonsei Med J 40(2), 144-51 (Fluox).
55. Paul, A. A., Leishman, D. J., Witchel, H. J., and Hancox, J. C. (2001). Effects of the class III antiarrhythmic agent dofetilide (UK-68,798) on L-type calcium current from rabbit ventricular myocytes. J Pharm Pharmacol 53(12), 1671-8 (Dofet).
56. Pettignano, R., Chambliss, R. C., Darsey, E., Heard, M., Michael, R. N., and Reese, C. (1996). Cisapride-induced dysrhythmia in a pediatric patient receiving extracorporeal life support [Case Report]. Critical Care Med 24(7), 1268-71.
57. Rampe, D., Murawsky, M. K., Grau, J., and Lewis, E. W. (1998). The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther. 286(2), 788-93 (Dofet).
58. Rampe, D., Roy, M-L., Dennis, A., and Brown, A. M. (1997). A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 417, 28-32 (Cisa, Terf).
59. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K. S., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J., and Hammond, T. G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsades de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58, 32-45 (Cisa, Dofet, Terf, Verap).
60. + efflux assay. J Biomolec Screen 9(7), 588-97.
61. Ridley, J. M., Dooley, P. C., Milnes, J. T., Witchel, H. J., and Hancox, J. C. (2004). Lidoflazine is a high affinity blocker of the HERG K(+)channel. J Mol Cell Cardiol 36(5), 701-5 (Verap).
62. Roden, D. M. (1998). Taking the "idio" out of "idiosyncratic": predicting Torsades de Pointes. PACE 21, 1029-34.
63. Roden, D. M. (2004). Drug therapy: drug-induced prolongation of the QT interval. N Engl J Med 350(10), 1013-22.
64. Rosen, M. R., Ilvento, J. P., Gelband, H., and Merker, C. (1974). Effects of verapamil on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 189(2), 414-22.
65. Roy, M. L., Dumaine, R., and Brown, A. M. (1996). HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94, 817-23
66. + current. Differential sensitivity to block by Class III antiarrhythmic agents. J Gen Physiol 96, 195-215.
67. Kr potassium channel. Cell 81, 299-307.
68. Shah, R. R., and Hondeghem, L. M. (2005). Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm 2(7), 758-72.
69. Smith, P. L., Baukrowitz, T., and Yellen, G. (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379, 833-36.
70. Snyders, D. J., and Chaudhary, A. (1996). High affinity open channel block by dofetilide of hERG expressed in a human cell line. Mol Pharmacol 49, 949-55 (Dofet).
71. Kr channel. J Gen. Physiol 107, 611-19.
72. + channel. J Mol Cell Cardiol 36(1), 151-60.
73. Tarantino, P., Appleton, N., and Lansdell, K. (2005). Effect of trazodone on hERG channel current and QT-interval. Eur J Pharmacol. 510(1-2), 75-85. (Cisa).
74. Thomas, D., Kiehn, J., Katus, H. A., and Karle, C. A. (2003). Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 60(2), 235-41.
75. Towbin, J. A., and Vatta, M. (2001). Molecular biology and the prolonged QT syndromes. Am J Med 110, 385-98.
76. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995). HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 269, 92-5.
77. Tsujimae, K., Suzuki, S., Yamada, M., and Kurachi, Y. (2004). Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. Eur J Pharmacol 493(1-3), 29-40.
78. Van Haarst, D. A., van't Klooster, G. A. E., van Gerven, J. M. A., Schoemaker, R. C., van Oene, J. C., Burggraaf, J., Coene, M.-C., and Cohen, A. F. (1998). The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 64, 542-6 (Cisa).
79. Wang, J., Della-Penna, K., Wang, H., Karczewski, J., Connolly, T. M., Koblan, K. S., Bennett, P. B., and Salata, J. J. (2003). Functional and pharmacological properties of canine ERG potassium channels. Am J Physiology (Heart Circ Physiol) 284(1), H256-67 (Cisa).
80. Weerapura, M., Hebert, T. E., and Nattel, S. (2002). Dofetilide block involves interactions with open and inactivated states of HERG channels. Pflugers Arch 443(4), 520-31.
81. + channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 48(2), 65-80.
82. Witchel, H. J., Pabbathi, V. K., Hofmann, G., Paul, A. A., and Hancox, J. C. (2002). Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and vetnricular L-type calcium currents. FEBS Lett 512, 59-66.(Floux).
83. Witchel, H. J., Dempsey, C. E., Sessions, R. B., Perry, M., Milnes, J. T., Hancox, J. C., and Mitcheson, J. S. (2004). The low-potency, voltage-dependent HERG blocker propafenone - molecular determinants and drug trapping. Mol Pharmacol 66(5), 1201-12.
84. Woosley, R. L., Chen, Y., Freiman, J. P., and Gillis, R. A. (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA 269(12), 1532-6 (Terf).
85. Yan, G. X., Wu, Y., Liu, T., Wang, J., Marinchak, R. A., and Kowey, P. R. (2001). Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome: direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 103(23), 2851-6.
86. Yang, T., Snyders, D., and Roden, D. M. (2001). Drug block of I(kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 38(5), 737-44 (Verap).
87. Yao, J.-A., Du, X., Lu, D., Baker, R. L., Daharsh, E., and Atterson, P. (2005). Estimation of potency of hERG channel blockers: Impact of voltage protocol and temperature. J Pharmacol Toxicol Meth 52, 146-53.
88. Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., and Viskin, S. (2003). Torsade de Pointes due to noncardiac drugs: Most patients have easily identifiable risk factors. Medicine 82(4), 282-90.
89. Zhang, S., Zhou, Z., Gong, Q., Makielski, J. C., and January, C. T. (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium Channels. Circ. Res 84, 989-98 (Verap).
90. Zhou, Z., Gong, Q., Ye, B., Fan, Z., Makielski, J. C., Robertson, G. A., and January, C. T. (1998). Properties of hERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74, 230-41.